William H. Bradley, MD, on Ovarian Cancer: 5-Year Follow-up on Maintenance Olaparib

March 20, 2021 By The ASCO Post Staff

William H. Bradley, MD, of the Medical College of Wisconsin, discusses results from the SOLO-1 trial on maintenance olaparib after first-line platinum-based chemotherapy for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. Almost half of the patients treated with olaparib in the study were disease-free at 5 years, vs 20% of those treated with placebo (ID# 10224).

Related Content